Aayush Wellness Ltd to Foray into Diagnostic Testing and Tele Consultation Segment
VMPL
New Delhi [India], June 21: Aayush Wellness Limited [BSE:539528], India's Integrated Healthcare Company, which already operates a Primary healthcare center has announced its foray into diagnostic testing, home sample collection And Teleconsultation segment. These services shall be offered through website and mobile app specifically designed to make essential health services more accessible and affordable, especially for families and working individuals who want straightforward healthcare from home.
Key Services Offered:
-Diagnostic Testing: Wide range of lab tests including blood work, health panels, and preventive screenings.
-Home Sample Collection: Hassle-free sample collection from the comfort of home, ensuring convenience and time savings.
-Teleconsultation: Access to qualified doctors through video consultations for timely medical advice and follow-ups.
-Digital Access: Lab reports and prescriptions accessible through a dedicated website and mobile app.
The diagnostics market in India is currently valued at Rs. 1.11 lakh crores, growing at CAGR of 14%, with home sample collection projected to contribute nearly 25 to 30 percent of this share in the coming year. Recognizing this rising demand for doorstep healthcare solutions, Aayush Wellness Limited sees a strong opportunity to grow and expand its footprint across India. By combining user-friendly digital interfaces with dependable on-ground services, the company aims to capture this high-growth segment and redefine how healthcare is delivered--making it faster, more accessible, and truly patient-first.
In today's fragmented healthcare system, accessing even basic services like diagnostic tests or follow-up consultations often involves long delays, confusing procedures, and high costs. Aayush Wellness Limited is changing that by offering a unified digital platform that brings home sample collection, lab reports, and doctor consultations under one roof. By streamlining the entire journey and eliminating unnecessary intermediaries, the platform not only saves time but also makes quality healthcare more affordable and accessible for every household.
By making preventive checkups and medical advice easily accessible, Aayush Wellness isn't just offering convenience--it's empowering individuals to take proactive control of their health. Whether it's patients managing chronic conditions, seniors needing regular monitoring, or busy professionals who often postpone routine care, this digital-first approach ensures healthcare fits seamlessly into their daily lives.
"Our goal is to bring the simplicity and reliability to every household--where booking a test or consulting a doctor is as easy as ordering groceries online. We're entering this segment with a focus on affordability, trust, and convenience. This is more than a business expansion--it's a step towards reshaping everyday healthcare for millions." Said Mr. Naveena Kumar, Managing Director of Aayush Wellness Limited.
With this expansion, Aayush Wellness Limited is building a vertically integrated ecosystem that touches every stage of the preventive care journey--from test booking to diagnosis and treatment. The company's diversified model across wellness, nutraceuticals, herbal products, and now diagnostics, reduces risk and improves revenue visibility.
About Aayush Wellness Limited: (ISO 9000 and 22000 certified company)
Aayush Wellness Limited [BSE scrip code: 539528], established in 1989 is a pioneering name in health and wellness solutions, dedicated to offering products that merge wellbeing with innovation. We are India's preventive healthcare company committed to offer quality products and services to enhance the consumer well-being. Aayush Wellness continues to lead the industry in promoting healthier lifestyle choices through its diverse range of wellness products and services. For more information, please visit www.aayushwellness.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Standard
34 minutes ago
- Business Standard
Abram Food Limited plans to raise up to Rs. 13.99 crore from public issue, IPO opens on June 24th 2025
PNN New Delhi [India], June 21: New Delhi based Abram Food Limited is planning to raise Rs. 13.99 crore from its SME public issue. Incorporated in the year 2009, the company is engaged in the manufacturing and trading of Chana Dal, Flour (Chakki Atta), Besan, Multi Grain Atta, Maida, Sooji, Spices, Cattle Feed (Khal), and Edible Oils. The company has received approval to launch its public issue on BSE SME Platform. The public issue open for subscription on Tuesday, June 24th 2025 and closes on Thursday, June 26th 2025. Corporate Makers Capital Ltd is the Lead Manager to the Issue. The initial public offering of Rs. 13.99 crore is entirely a fresh issue of 14.28 lakh equity shares for a face value of Rs. 10 each with issue price fixed at Rs. 98 per equity share. Out of the fresh issue of Rs. 13.99 crore, company plans to utilize Rs. 3.85 crore towards capital expenditure for purchase of machineries, Rs. 6.70 crore towards funding of working capital requirement of the company, and rest for general corporate purpose. The minimum lot size for an application is 1,200. Retail investors are required to invest minimum amount of Rs. 1,17,600 whereas HNIs have to park Rs. 2,35,200 for minimum lot size of 2 lots (2,400 shares). Out of total 14,28,000 shares offered, 47.48% are reserved for the retail quota and 47.48% for HNI quota. Incorporated in 2009, Abram Food Limited is engaged in the manufacturing and trading of Chana Dal, Flour (Chakki Atta), Besan, Multi Multi-Gain Atta, Maida, Sooji, Spices, Cattle Feed (Khal), and Edible oils. It markets and sells its product range in Rajasthan, Delhi/NCR, and Uttar Pradesh under the brand name "Kherliwala" through a network of distributors. The company also send their products under the various brands i.e. Rajasthan Royal, Black Buck, Double Moonch, Origo Natural, Karwan. Highlights: -Fresh public issue of Rs. 13.99 crore opens for subscription from June 24th 2025 to June 26th 2025. -Minimum lot size for application is 1,200 shares; The minimum amount of investment required by retail investors is Rs. 1,17,600 whereas for HNI, the required investment will be amounting to Rs. 2,35,200 for 2,400 shares. -Funds raised through the issue will be used for capital expenditure for purchase of machineries, funding of working capital requirement of the company and for general corporate purposes. -For FY24-25 company reported total revenue of Rs. 64.09 crore and net profit of Rs. 3.26 crore. -As on 31 March 2025, ROE at 38.62%, ROCE at 56.02% and EPS at 9.05 and P/E(x) at 10.83. -The company Market Cap to Sales Ratio is 0.58 which is seems to be best in the industry. -Corporate Makers Capital Ltd is the Lead Manager to the Issue. The company also provide Chana Dal, Atta, Besan, Chana Churi and Cattle Feed (Khal) to its distributors in bulk quantities of ranging from 30 to 50 kg packaging to sell in loose quantity to end customer through retail outlets. By prioritizing traditional processing techniques and in-house manufacturing practices, the company ensures that each product captures the authentic "Taste of Rajasthan" delighting consumers with every bite. For FY24-25 ended on 31 March 2025, the company's total revenue increased by 78% to Rs. 64.09 crore against Rs. 36.14 crore in FY 2024. The company's net profit jumped significantly by 220% to Rs. 3.26 crore after Tax in 2025 against Rs. 1.02 crore after Tax in 2024, with a healthy EBIDTA margin of 7.92%. The Company is expecting a Growth of 56% in revenue and 26% in Net profit after Tax in the Financial year 2025-2026 by utilising the IPO proceeds. IPO Highlights- Abram Food Ltd IPO Opens on - June 24, 2025 IPO Closes on - June 26, 2025 Issue Price (Fixed) - Rs. 98 Per Share Issue Size - 14.28 lakh shares - Rs. 13.99 crore Lot Size - 1,200 Shares Listing on - BSE SME Platform (ADVERTORIAL DISCLAIMER: The above press release has been provided by PNN. ANI will not be responsible in any way for the content of the same)
Time of India
37 minutes ago
- Time of India
Delhi consumer panel upholds verdict indicting Dr Lal Pathlabs for wrong report
New Delhi: The Delhi State Consumer Disputes Redressal Commission has upheld a finding on Dr Lal Pathlabs being deficient in service and ordering it pay compensation to a patient over a wrong lab report . The state consumer commission's president Sangita Dhingra Sehgal and judicial member Pinki were hearing the lab's appeal against the August 2014 order of a district forum indicting the lab for a wrong test report and ordering Rs 3.5 lakh compensation. In its order on May 26, the commission said, "When a patient's urea levels are reported at more than ten times the normal range, triggering emergency hospitalisation and profound distress, the laboratory cannot retreat behind semantic arguments about its limited role in the diagnostic chain. Moreover, the appellant's (Lal Pathlabs) attempt to shift blame onto prescribing physicians or the Respondent's medical history holds no ground." It said if the tests carried out by a laboratory are defective and erroneous, the diagnosis by a doctor will be incorrect, resulting in improper treatment and the "medicines prescribed based on a wrong test report and diagnosis may lead to fatal results for the patient". "When multiple test reports from different laboratories show consistent results that differ significantly from one laboratory's findings, it creates a strong presumption of deficiency in service by the outlier laboratory," the commission added. Rejecting the lab's argument that the results were due to a particular drug consumed by the complainant, the commission said, "Even if it is assumed that the respondent (complainant) was taking Spirex tablets, we find it implausible that there could be such astronomical difference in patient's test reports pertaining to creatine and urea." It also rejected the lab's argument that the complainant did not agree to their request for re-collecting the sample, saying the report depicted the values of various important health indicators to be so high that any person having ordinary prudence would be perturbed by such results. "The respondent was under no obligation to get the tests redone. He got another test done from 3 labs, viz. Max Health Care, Dr Dangs Laboratory and Super Religare Laboratories Ltd, all of which depicted his parameters to be within the normal range," the commission said. The medical expenses incurred by the patient, in the panel's opinion, were directly attributable to the lab's erroneous report, which falsely indicated life-threatening conditions and necessitated emergency hospitalisation. The commission noted the discharge summary from Max Hospital "explicitly" linking the patient's admission there to the "erroneous outside lab report". "Being misdiagnosed with life-threatening conditions and undergoing unnecessary hospitalisation constitutes severe psychological trauma. The mental agony and physical suffering cannot be understated." The panel found the direction for compensation "just and reasonable". "We concur with the district commission's finding that the appellant failed to maintain the standard of reasonable care expected in pathological testing, thus amounting to a deficiency in service," it held.
Time of India
an hour ago
- Time of India
Ahmedabad crash aftermath: Air India begins Rs 25 lakh interim payouts; trauma support offered to affected families
Air India has started releasing interim compensation of Rs 25 lakh each to the families of the deceased and survivors of the Boeing 787-8 plane crash that occurred in Ahmedabad on 12 June. In a statement issued on Saturday, the airline confirmed that three families have received payments so far, with the rest currently being processed. The compensation rollout began on 20 June. This interim support comes in addition to the Rs 1 crore compensation previously announced by Tata Sons, Air India's parent company. To aid grieving families, Air India has deployed a team of trained psychologists and doctors in Ahmedabad to provide trauma counselling and emotional support. A separate team comprising medical personnel, including nurses and a pharmacist, is addressing ongoing and emerging health needs. A helpdesk, active since 15 June, is assisting families with documentation and claim processing. The airline said this single-window system is helping speed up the compensation procedure. The team of medical personnel, including nurses and a pharmacist has been deployed to address ongoing or emerging health needs, Air India said. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Buy Brass Laxmi Ji Idol For Wealth, Peace & Happiness Luxeartisanship Shop Now Undo The airline added that assistance is being extended to families through DNA identification procedures, and at least one caregiver is accompanying each family when mortal remains are released, ensuring respectful transport and funeral arrangements. Additional financial aid, covering travel, medical expenses, accommodation and funeral costs, is also being provided based on individual needs.
